INM — InMed Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1728328 ·
British Columbia, Canada
Last close
$1.38
Market Cap
$7.58M
52W High
$2.50
52W Low
$0.57
ADV30
79,400
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,211,149 | -5,839,392 | 3,030,067 | 2,194,413 | 1,955,060 |
| Mar 2026 | 0 | — | -2,816,353 | -2,966,336 | 9,133,806 | 5,158,932 | 2,242,032 |
| Dec 2025 | 820,188 | 184,194 | -2,120,738 | -2,028,223 | 11,191,484 | 6,954,834 | 1,603,820 |
| Sep 2025 | 1,120,121 | 403,159 | -1,763,670 | -1,726,899 | 13,361,085 | 9,331,077 | 1,770,462 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,161,399
Investing CF
$0
Financing CF
$94,496
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.62
As of
2026-09-13
Balance + Analyst (yfinance extras)
Retained Earnings
$-130,230,406
Inventory
$947,898
Receivables
$182,967
ST Investments
—
EBIT TTM
$-11,416,006
Pretax Income TTM
$-11,389,935
Interest Exp TTM
$30,700
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,942,633
EBITDA
$-7,834,568
Free Cash Flow
$-3,935,634
Enterprise Value
$-438,987
Total Cash
$5,200,557
Total Debt
$420,147
Shares Out
5,493,735
Trailing EPS
$-2.84
Book Value
$2.08
ROE
-112.6%
ROA
-54.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | -9,895,116 | -12,560,850 | 3,030,067 | 1,955,060 | 1,075,007 | -8,643,513 |
| Jun 2025 | 0 | -8,446,170 | -8,162,133 | 15,580,040 | 2,145,545 | 13,434,495 | -8,099,392 |
| Jun 2024 | 4,597,730 | -8,134,430 | -7,675,550 | 11,822,782 | 2,616,673 | 9,206,109 | -6,985,832 |
| Jun 2023 | 4,135,561 | -8,378,787 | -7,947,622 | 14,106,340 | 2,016,613 | 12,089,727 | -7,283,199 |
| Jun 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CURX | Curanex Pharmaceuticals Inc | $7.43M | $4.74 | — |
| SKYE | Skye Bioscience, Inc. | $7.39M | $1.67 | — |
| HEPA | Hepion Pharmaceuticals, Inc. | $7.85M | $0.09 | — |
| INNPF | INNOCAN PHARMA Corp | $7.29M | $1.62 | — |
| IMNN | Imunon, Inc. | $7.91M | $1.41 | — |
News headlines (Yahoo Finance, 1h cache)
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
2026-06-04 21:00 · Yahoo
INM Stock Alert: What to Know as InMed, Mentari Announce Merger
2026-05-20 17:01 · Yahoo
/C O R R E C T I O N -- InMed Pharmaceuticals/
2026-05-20 14:34 · Yahoo
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM)
2026-05-19 14:37 · Yahoo
InMed Pharmaceuticals Amends Preferred Investment Options
2026-05-19 10:00 · Yahoo
A migraine drugmaker heads to the public markets through reverse merger
2026-05-19 11:19 · Yahoo
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
2026-05-06 22:00 · Yahoo
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
2026-09-18 20:45 · Yahoo
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
2026-09-09 20:30 · Yahoo
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
2026-07-22 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.